{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T06:14:43Z","timestamp":1793859283336,"version":"4.6.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T00:00:00Z","timestamp":1633996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T00:00:00Z","timestamp":1633996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Systemic sclerosis (SSc) is a chronic multisystem disorder characterized by fibrosis and autoimmunity. Interleukin (IL)-31 has been implicated in fibrosis and T helper (Th) 2 immune responses, both of which are characteristics of SSc. The exact role of IL-31 in SSc pathogenesis is unclear. Here we show the overexpression of IL-31 and IL-31 receptor A (IL-31RA) in dermal fibroblasts (DFs) from SSc patients. We elucidate the dual role of IL-31 in SSc, where IL-31 directly promotes collagen production in DFs and indirectly enhances Th2 immune responses by increasing pro-Th2 cytokine expression in DFs. Furthermore, blockade of IL-31 with anti-IL-31RA antibody significantly ameliorates fibrosis and Th2 polarization in a mouse model of SSc. Therefore, in addition to defining IL-31 as a mediator of fibrosis and Th2 immune responses in SSc, our study provides a rationale for targeting the IL-31\/IL-31RA axis in the treatment of SSc.<\/jats:p>","DOI":"10.1038\/s41467-021-26099-w","type":"journal-article","created":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T13:24:52Z","timestamp":1634045092000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":88,"title":["Interleukin-31 promotes fibrosis and T helper 2 polarization in systemic sclerosis"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2261-7469","authenticated-orcid":false,"given":"Ai","family":"Kuzumi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8194-9140","authenticated-orcid":false,"given":"Ayumi","family":"Yoshizaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6755-8047","authenticated-orcid":false,"given":"Kazuki M.","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohito","family":"Kotani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Norimatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maiko","family":"Fukayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Ebata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takemichi","family":"Fukasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asako","family":"Yoshizaki-Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihide","family":"Asano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyojiro","family":"Morikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Kazoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuma","family":"Mawatari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiko","family":"Kitamori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,12]]},"reference":[{"key":"26099_CR1","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1056\/NEJMra0806188","volume":"360","author":"A Gabrielli","year":"2009","unstructured":"Gabrielli, A., Avvedimento, E. V. & Krieg, T. Scleroderma. N. Engl. J. Med. 360, 1989\u20132003 (2009).","journal-title":"N. Engl. J. Med."},{"key":"26099_CR2","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.imlet.2018.01.002","volume":"195","author":"A Yoshizaki","year":"2018","unstructured":"Yoshizaki, A. Pathogenic roles of B lymphocytes in systemic sclerosis. Immunol. Lett. 195, 76\u201382 (2018).","journal-title":"Immunol. Lett."},{"key":"26099_CR3","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1093\/rheumatology\/kes090","volume":"51","author":"S O\u2019Reilly","year":"2012","unstructured":"O\u2019Reilly, S., H\u00fcgle, T. & van Laar, J. M. T cells in systemic sclerosis: a reappraisal. Rheumatology 51, 1540\u20131549 (2012).","journal-title":"Rheumatology"},{"key":"26099_CR4","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1002\/art.1780270607","volume":"27","author":"AD Roumm","year":"1984","unstructured":"Roumm, A. D., Whiteside, T. L., Medsger, T. A. Jr. & Rodnan, G. P. Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. Arthritis Rheum. 27, 645\u2013653 (1984).","journal-title":"Arthritis Rheum."},{"key":"26099_CR5","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1136\/ard.2004.027094","volume":"64","author":"A Kalogerou","year":"2005","unstructured":"Kalogerou, A. et al. Early T cell activation in the skin from patients with systemic sclerosis. Ann. Rheum. Dis. 64, 1233\u20131235 (2005).","journal-title":"Ann. Rheum. Dis."},{"key":"26099_CR6","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1136\/ard.52.4.272","volume":"52","author":"U Fiocco","year":"1993","unstructured":"Fiocco, U. et al. Early phenotypic activation of circulating helper memory T cells in scleroderma: correlation with disease activity. Ann. Rheum. Dis. 52, 272\u2013277 (1993).","journal-title":"Ann. Rheum. Dis."},{"key":"26099_CR7","doi-asserted-by":"publisher","first-page":"G723","DOI":"10.1152\/ajpgi.00414.2010","volume":"300","author":"L Barron","year":"2011","unstructured":"Barron, L. & Wynn, T. A. Fibrosis is regulated by Th2 and Th17 responses and by dynamic interactions between fibroblasts and macrophages. Am. J. Gastrointest. Liver Physiol. 300, G723\u2013G728 (2011).","journal-title":"Am. J. Gastrointest. Liver Physiol."},{"key":"26099_CR8","first-page":"328","volume":"24","author":"M Hasegawa","year":"1997","unstructured":"Hasegawa, M., Fujimoto, M., Kikuchi, K. & Takehara, K. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J. Rheumatol. 24, 328\u2013332 (1997).","journal-title":"J. Rheumatol."},{"key":"26099_CR9","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1001\/archderm.1996.03890310088013","volume":"132","author":"V Salmon-Ehr","year":"1996","unstructured":"Salmon-Ehr, V. et al. Expression of interleukin-4 in scleroderma skin specimens and scleroderma fibroblast cultures. Potential role in fibrosis. Arch. Dermatol. 132, 802\u2013806 (1996).","journal-title":"Arch. Dermatol."},{"key":"26099_CR10","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.4049\/jimmunol.0901778","volume":"185","author":"A Yoshizaki","year":"2010","unstructured":"Yoshizaki, A. et al. Cell adhesion molecules regulate fibrotic process via Th1\/Th2\/Th17 Cell Balance in a bleomycin-induced scleroderma model. J. Immunol. 185, 2502\u20132515 (2010).","journal-title":"J. Immunol."},{"key":"26099_CR11","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1046\/j.1523-1747.1999.00528.x","volume":"112","author":"T Yamamoto","year":"1999","unstructured":"Yamamoto, T. et al. Animal model of sclerotic skin. I: Local injections of bleomycin induce sclerotic skin mimicking scleroderma. J. Invest. Dermatol. 112, 456\u2013462 (1999).","journal-title":"J. Invest. Dermatol."},{"key":"26099_CR12","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1172\/JCI116015","volume":"90","author":"AE Postlethwaite","year":"1992","unstructured":"Postlethwaite, A. E., Holness, M. A., Katai, H. & Raghow, R. Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. J. Clin. Invest. 90, 1479\u20131485 (1992).","journal-title":"J. Clin. Invest."},{"key":"26099_CR13","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1084\/jem.194.6.809","volume":"194","author":"CG Lee","year":"2001","unstructured":"Lee, C. G. et al. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor \u03b21. J. Exp. Med. 194, 809\u2013821 (2001).","journal-title":"J. Exp. Med."},{"key":"26099_CR14","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/362245a0","volume":"362","author":"M Kopf","year":"1993","unstructured":"Kopf, M. et al. Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature 362, 245\u2013248 (1993).","journal-title":"Nature"},{"key":"26099_CR15","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/S0923-1811(01)00128-1","volume":"27","author":"S Sato","year":"2001","unstructured":"Sato, S., Hasegawa, M. & Takehara, K. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J. Dermatol. Sci. 27, 140\u2013146 (2001).","journal-title":"J. Dermatol. Sci."},{"key":"26099_CR16","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1159\/000163802","volume":"61","author":"AE Koch","year":"1993","unstructured":"Koch, A. E. et al. In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis. Pathobiology 61, 239\u2013246 (1993).","journal-title":"Pathobiology"},{"key":"26099_CR17","doi-asserted-by":"publisher","first-page":"9952","DOI":"10.1074\/jbc.M113.545822","volume":"289","author":"S O\u2019Reilly","year":"2014","unstructured":"O\u2019Reilly, S., Ciechomska, M., Cant, R. & van Laar, J. M. Interleukin-6 (IL-6) trans signaling drives a STAT3-dependent pathway that leads to hyperactive transforming growth factor-\u03b2 (TGF-\u03b2) signaling promoting SMAD3 activation and fibrosis via Gremlin protein. J. Biol. Chem. 289, 9952\u20139960 (2014).","journal-title":"J. Biol. Chem."},{"key":"26099_CR18","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1084\/jem.185.3.461","volume":"185","author":"M Rinc\u00f3n","year":"1997","unstructured":"Rinc\u00f3n, M., Anguita, J., Nakamura, T., Fikrig, E. & Flavell, R. A. Interleukin (IL)-6 directs the differentiation of IL-4-producing CD4+ T cells. J. Exp. Med. 185, 461\u2013469 (1997).","journal-title":"J. Exp. Med."},{"key":"26099_CR19","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1038\/ni1084","volume":"5","author":"SR Dillon","year":"2004","unstructured":"Dillon, S. R. et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat. Immunol. 5, 752\u2013760 (2004).","journal-title":"Nat. Immunol."},{"key":"26099_CR20","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.jaci.2017.10.045","volume":"141","author":"IS Ba\u011fci","year":"2018","unstructured":"Ba\u011fci, I. S. & Ruzicka, T. IL-31: A new key player in dermatology and beyond. J. Allergy Clin. Immunol. 141, 858\u2013866 (2018).","journal-title":"J. Allergy Clin. Immunol."},{"key":"26099_CR21","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.jaci.2016.06.033","volume":"138","author":"M Akdis","year":"2016","unstructured":"Akdis, M. et al. Interleukins (from IL-1 to IL-38), interferons, transforming growth factor \u03b2, and TNF-\u03b1: Receptors, functions, and roles in diseases. J. Allergy Clin. Immunol. 138, 984\u20131010 (2016).","journal-title":"J. Allergy Clin. Immunol."},{"key":"26099_CR22","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.ejcb.2011.07.006","volume":"91","author":"C Cornelissen","year":"2012","unstructured":"Cornelissen, C., L\u00fcscher-Firzlaff, J., Baron, J. M. & L\u00fcscher, B. Signaling by IL-31 and functional consequences. Eur. J. Cell Biol. 91, 552\u2013566 (2012).","journal-title":"Eur. J. Cell Biol."},{"key":"26099_CR23","doi-asserted-by":"publisher","first-page":"3014","DOI":"10.1074\/jbc.M609655200","volume":"282","author":"S Chattopadhyay","year":"2007","unstructured":"Chattopadhyay, S. et al. Interleukin-31 and oncostatin-M mediate distinct signaling reactions and response patterns in lung epithelial cells. J. Biol. Chem. 282, 3014\u20133026 (2007).","journal-title":"J. Biol. Chem."},{"key":"26099_CR24","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/j.1365-2567.2007.02668.x","volume":"122","author":"WK Ip","year":"2007","unstructured":"Ip, W. K. et al. Interleukin-31 induces cytokine and chemokine production from human bronchial epithelial cells through activation of mitogen-activated protein kinase signaling pathways: implications for the allergic response. Immunology 122, 532\u2013541 (2007).","journal-title":"Immunology"},{"key":"26099_CR25","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/j.1398-9995.2007.01566.x","volume":"63","author":"Z Lei","year":"2008","unstructured":"Lei, Z. et al. SCF and IL-31 rather than IL-17 and BAFF are potential indicators in patients with allergic asthma. Allergy 63, 327\u2013332 (2008).","journal-title":"Allergy"},{"key":"26099_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/srep22835","volume":"6","author":"T Lai","year":"2016","unstructured":"Lai, T. et al. Interleukin-31 expression and relation to disease severity in human asthma. Sci. Rep. 6, 22835 (2016).","journal-title":"Sci. Rep."},{"key":"26099_CR27","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.jaci.2006.07.015","volume":"118","author":"MM Neis","year":"2006","unstructured":"Neis, M. M. et al. Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis. J. Allergy Clin. Immunol. 118, 930\u2013937 (2006).","journal-title":"J. Allergy Clin. Immunol."},{"key":"26099_CR28","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.jaci.2008.05.047","volume":"122","author":"U Raap","year":"2008","unstructured":"Raap, U. et al. Correlation of IL-31 serum levels with severity of atopic dermatitis. J. Allergy Clin. Immunol. 122, 421\u2013423 (2008).","journal-title":"J. Allergy Clin. Immunol."},{"key":"26099_CR29","doi-asserted-by":"publisher","first-page":"282","DOI":"10.2340\/00015555-1345","volume":"92","author":"H Ohmatsu","year":"2012","unstructured":"Ohmatsu, H. et al. Serum IL-31 levels are increased in patients with cutaneous T-cell lymphoma. Acta Derm. Venereol. 92, 282\u2013283 (2012).","journal-title":"Acta Derm. Venereol."},{"key":"26099_CR30","doi-asserted-by":"publisher","first-page":"894","DOI":"10.2340\/00015555-2417","volume":"96","author":"LA Nattkemper","year":"2016","unstructured":"Nattkemper, L. A. et al. Cutaneous T-cell lymphoma and pruritus: the expression of IL-31 and its receptors in the skin. Acta Derm. Venereol. 96, 894\u2013898 (2016).","journal-title":"Acta Derm. Venereol."},{"key":"26099_CR31","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1056\/NEJMoa1606490","volume":"376","author":"T Ruzicka","year":"2017","unstructured":"Ruzicka, T. et al. Anti-Interleukin-31 receptor A antibody for atopic dermatitis. N. Engl. J. Med. 376, 826\u2013835 (2017).","journal-title":"N. Engl. J. Med."},{"key":"26099_CR32","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1089\/vim.2014.0142","volume":"28","author":"D Ming","year":"2012","unstructured":"Ming, D. et al. Elevated TGF-\u03b21\/IL-31 pathway is associated with the disease severity of hepatitis B virus-related liver cirrhosis. Viral Immunol. 28, 209\u2013216 (2012).","journal-title":"Viral Immunol."},{"key":"26099_CR33","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.resp.2013.09.011","volume":"190","author":"K Shi","year":"2014","unstructured":"Shi, K. et al. Pathogenesis pathways of idiopathic pulmonary fibrosis in bleomycin-induced lung injury model in mice. Respir. Physiol. Neurobiol. 190, 113\u2013117 (2014).","journal-title":"Respir. Physiol. Neurobiol."},{"key":"26099_CR34","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1093\/rheumatology\/keaa195","volume":"59","author":"B Yaseen","year":"2020","unstructured":"Yaseen, B. et al. Interleukin-31 promotes pathogenic mechanisms underlying skin and lung fibrosis in scleroderma. Rheumatology 59, 2625\u20132636 (2020).","journal-title":"Rheumatology"},{"key":"26099_CR35","first-page":"1892","volume":"20","author":"PJ Clements","year":"1993","unstructured":"Clements, P. J. et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J. Rheumatol. 20, 1892\u20131896 (1993).","journal-title":"J. Rheumatol."},{"key":"26099_CR36","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1002\/jcp.20251","volume":"203","author":"S Chujo","year":"2005","unstructured":"Chujo, S. et al. Connective tissue growth factor causes persistent proalpha2(I) collagen gene expression induced by transforming growth factor-beta in a mouse fibrosis model. J. Cell Physiol. 203, 447\u2013456 (2005).","journal-title":"J. Cell Physiol."},{"key":"26099_CR37","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1042\/bj2470597","volume":"247","author":"J Varga","year":"1987","unstructured":"Varga, J. et al. Transforming growth factor beta (TGF beta) causes a persistent increase in steady-state amounts of type I and type III collagen and fibronectin mRNAs in normal human dermal fibroblasts. Biochem. J. 247, 597\u2013604 (1987).","journal-title":"Biochem. J."},{"key":"26099_CR38","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1186\/s13075-014-0411-6","volume":"16","author":"PS Tsou","year":"2014","unstructured":"Tsou, P. S. et al. Lipoic acid plays a role in scleroderma: insights obtained from scleroderma dermal fibroblasts. Arthritis Res. Ther. 16, 411 (2014).","journal-title":"Arthritis Res. Ther."},{"key":"26099_CR39","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/nrrheum.2011.149","volume":"8","author":"S Bhattacharyya","year":"2011","unstructured":"Bhattacharyya, S., Wei, J. & Varga, J. Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat. Rev. Rheumatol. 8, 42\u201354 (2011).","journal-title":"Nat. Rev. Rheumatol."},{"key":"26099_CR40","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1136\/annrheumdis-2011-200955","volume":"71","author":"K Khan","year":"2012","unstructured":"Khan, K. et al. Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis. Ann. Rheum. Dis. 71, 1235\u20131242 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"26099_CR41","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1136\/ard.2009.119321","volume":"69","author":"M Manetti","year":"2010","unstructured":"Manetti, M. et al. The IL1-like cytokine IL33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis. Ann. Rheum. Dis. 69, 598\u2013605 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"26099_CR42","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1002\/art.40171","volume":"69","author":"M Wu","year":"2017","unstructured":"Wu, M. et al. CCL2 in the circulation predicts long-term progression of interstitial lung disease in patients with early systemic sclerosis: data from two independent cohorts. Arthritis Rheum. 69, 1871\u20131878 (2017).","journal-title":"Arthritis Rheum."},{"key":"26099_CR43","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1091\/mbc.E17-06-0342","volume":"29","author":"I Papaioannou","year":"2018","unstructured":"Papaioannou, I. et al. STAT3 controls COL1A2 enhancer activation cooperatively with JunB, regulates type I collagen synthesis posttranscriptionally, and is essential for lung myofibroblast differentiation. Mol. Biol. Cell. 29, 84\u201395 (2018).","journal-title":"Mol. Biol. Cell."},{"key":"26099_CR44","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1002\/art.41267","volume":"72","author":"Z Taki","year":"2020","unstructured":"Taki, Z. et al. Pathogenic activation of mesenchymal stem cells is induced by the disease microenvironment in systemic sclerosis. Arthritis Rheum. 72, 1361\u20131374 (2020).","journal-title":"Arthritis Rheum."},{"key":"26099_CR45","doi-asserted-by":"publisher","first-page":"3086","DOI":"10.1002\/art.30470","volume":"63","author":"A Yoshizaki","year":"2011","unstructured":"Yoshizaki, A. et al. The specific free radical scavenger edaravone suppresses fibrosis in the bleomycin-induced and tight skin mouse models of systemic sclerosis. Arthritis Rheum. 63, 3086\u20133097 (2011).","journal-title":"Arthritis Rheum."},{"key":"26099_CR46","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.jaci.2013.03.050","volume":"132","author":"B Stott","year":"2013","unstructured":"Stott, B. et al. Human IL-31 is induced by IL-4 and promotes TH2-driven inflammation. J. Allergy Clin. Immunol. 132, 446\u2013454 (2013).","journal-title":"J. Allergy Clin. Immunol."},{"key":"26099_CR47","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","volume":"72","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen, F. et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative. Ann. Rheum. Dis. 72, 1747\u20131755 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"26099_CR48","first-page":"202","volume":"15","author":"EC LeRoy","year":"1988","unstructured":"LeRoy, E. C. et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J. Rheumatol. 15, 202\u2013205 (1988).","journal-title":"J. Rheumatol."},{"key":"26099_CR49","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/art.1780370313","volume":"37","author":"S Sato","year":"1994","unstructured":"Sato, S., Ihn, H., Kikuchi, K. & Takehara, K. Antihistone antibodies in systemic sclerosis: association with pulmonary fibrosis. Arthritis Rheum. 37, 391\u2013394 (1994).","journal-title":"Arthritis Rheum."},{"key":"26099_CR50","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.2353\/ajpath.2008.071049","volume":"172","author":"A Yoshizaki","year":"2008","unstructured":"Yoshizaki, A. et al. CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma. Am. J. Pathol. 172, 1650\u20131663 (2008).","journal-title":"Am. J. Pathol."},{"key":"26099_CR51","doi-asserted-by":"publisher","first-page":"e86184","DOI":"10.1371\/journal.pone.0086184","volume":"9","author":"S Seeber","year":"2014","unstructured":"Seeber, S. et al. A robust high throughput platform to generate functional recombinant monoclonal antibodies using rabbit B cells from peripheral blood. PLoS ONE 9, e86184 (2014).","journal-title":"PLoS ONE"},{"key":"26099_CR52","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.1002\/art.34643","volume":"64","author":"Y Okamoto","year":"2012","unstructured":"Okamoto, Y. et al. Potential roles of interleukin-17A in the development of skin fibrosis in mice. Arthritis Rheum. 64, 3726\u20133735 (2012).","journal-title":"Arthritis Rheum."},{"key":"26099_CR53","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1136\/jcp.41.4.467","volume":"41","author":"T Ashcroft","year":"1988","unstructured":"Ashcroft, T., Simpson, J. M. & Timbrell, V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J. Clin. Pathol. 41, 467\u2013470 (1988).","journal-title":"J. Clin. Pathol."},{"key":"26099_CR54","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/nprot.2015.047","volume":"10","author":"K Moro","year":"2015","unstructured":"Moro, K., Ealey, K. N., Kabata, H. & Koyasu, S. Isolation and analysis of group 2 innate lymphoid cells in mice. Nat. Protoc. 10, 792\u2013806 (2015).","journal-title":"Nat. Protoc."},{"key":"26099_CR55","doi-asserted-by":"publisher","first-page":"976","DOI":"10.3899\/jrheum.080343","volume":"36","author":"Y Iwata","year":"2009","unstructured":"Iwata, Y. et al. Increased serum pentraxin 3 in patients with systemic sclerosis. J. Rheumatol. 36, 976\u2013983 (2009).","journal-title":"J. Rheumatol."},{"key":"26099_CR56","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.4049\/jimmunol.170.4.2083","volume":"170","author":"F Huaux","year":"2003","unstructured":"Huaux, F., Liu, T., McGarry, B., Ullenbruch, M. & Phan, S. H. Dual roles of IL-4 in lung injury and fibrosis. J. Immunol. 170, 2083\u20132092 (2003).","journal-title":"J. Immunol."},{"key":"26099_CR57","doi-asserted-by":"publisher","first-page":"e68380","DOI":"10.1371\/journal.pone.0068380","volume":"8","author":"I Ekoti","year":"2013","unstructured":"Ekoti, I., Brattig, N. W., Liebau, E. & Breloer, M. Nematode-derived proteins suppress proliferation and cytokine production of antigen-specific T cells via induction of cell death. PLoS ONE 8, e68380 (2013).","journal-title":"PLoS ONE"},{"key":"26099_CR58","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.1038\/jid.2008.136","volume":"128","author":"M Xue","year":"2008","unstructured":"Xue, M. et al. Autocrine actions of matrix metalloproteinase (MMP)-2 counter the effects of MMP-9 to promote survival and prevent terminal differentiation of cultured human keratinocytes. J. Invest. Dermatol. 128, 2676\u20132685 (2008).","journal-title":"J. Invest. Dermatol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-26099-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-26099-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-26099-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T16:02:46Z","timestamp":1669996966000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-26099-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,12]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["26099"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-26099-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,12]]},"assertion":[{"value":"14 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5947"}}